Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia

Y. Yogev, R. Chen, M. Hod, D.R. Coustan, J.J.N. Oats, B.E. Metzger, L.P. Lowe, A.R. Dyer, Elizabeth Trimble, David McCance

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Objective: The purpose of this study was to examine associations of fasting C-peptide, body mass index (BMI), and maternal glucose with the risk of preeclampsia in a multicenter multinational study. Study Design: We conducted a secondary analysis of a blinded observational cohort study. Subjects underwent a 75-g oral glucose tolerance test at 24-32 weeks' gestation. Associations of preeclampsia with fasting C-peptide, BMI, and maternal glucose were assessed with the use of multiple logistic regression analyses and adjustment for potential confounders. Results: Of 21,364 women who were included in the analyses, 5.2% had preeclampsia. Adjusted odds ratios for preeclampsia for 1 SD higher fasting C-peptide (0.87 ug/L), BMI (5.1 kg/m), and fasting (6.9 mg/dL), 1-hour (30.9 mg/dL), and 2-hour plasma glucose (23.5 mg/dL) were 1.28 (95% confidence interval [CI], 1.20-1.36), 1.60 (95% CI, 1.60-1.71), 1.08 (95% CI, 1.00-1.16), 1.19 (95% CI, 1.11-1.28), and 1.21 (95% CI,1.13-1.30), respectively. Conclusion: Results indicate strong, independent associations of fasting C-peptide and BMI with preeclampsia. Maternal glucose levels (below diabetes mellitus) had weaker associations with preeclampsia, particularly after adjustment for fasting C-peptide and BMI.
Original languageEnglish
JournalAmerican Journal of Obstetrics and Gynecology
Volume202
Issue number3
DOIs
Publication statusPublished - 01 Mar 2010

Fingerprint

Pregnancy Outcome
Pre-Eclampsia
C-Peptide
Hyperglycemia
Fasting
Outcome Assessment (Health Care)
Body Mass Index
Confidence Intervals
Glucose
Mothers
Glucose Tolerance Test
Multicenter Studies
Observational Studies
Diabetes Mellitus
Cohort Studies
Logistic Models
Odds Ratio
Regression Analysis
Pregnancy

Cite this

Yogev, Y., Chen, R., Hod, M., Coustan, D. R., Oats, J. J. N., Metzger, B. E., ... McCance, D. (2010). Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia. American Journal of Obstetrics and Gynecology, 202(3). https://doi.org/10.1016/j.ajog.2010.01.024
Yogev, Y. ; Chen, R. ; Hod, M. ; Coustan, D.R. ; Oats, J.J.N. ; Metzger, B.E. ; Lowe, L.P. ; Dyer, A.R. ; Trimble, Elizabeth ; McCance, David. / Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study : preeclampsia. In: American Journal of Obstetrics and Gynecology. 2010 ; Vol. 202, No. 3.
@article{f7eecc23da484e838c06ecaf18541335,
title = "Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia",
abstract = "Objective: The purpose of this study was to examine associations of fasting C-peptide, body mass index (BMI), and maternal glucose with the risk of preeclampsia in a multicenter multinational study. Study Design: We conducted a secondary analysis of a blinded observational cohort study. Subjects underwent a 75-g oral glucose tolerance test at 24-32 weeks' gestation. Associations of preeclampsia with fasting C-peptide, BMI, and maternal glucose were assessed with the use of multiple logistic regression analyses and adjustment for potential confounders. Results: Of 21,364 women who were included in the analyses, 5.2{\%} had preeclampsia. Adjusted odds ratios for preeclampsia for 1 SD higher fasting C-peptide (0.87 ug/L), BMI (5.1 kg/m), and fasting (6.9 mg/dL), 1-hour (30.9 mg/dL), and 2-hour plasma glucose (23.5 mg/dL) were 1.28 (95{\%} confidence interval [CI], 1.20-1.36), 1.60 (95{\%} CI, 1.60-1.71), 1.08 (95{\%} CI, 1.00-1.16), 1.19 (95{\%} CI, 1.11-1.28), and 1.21 (95{\%} CI,1.13-1.30), respectively. Conclusion: Results indicate strong, independent associations of fasting C-peptide and BMI with preeclampsia. Maternal glucose levels (below diabetes mellitus) had weaker associations with preeclampsia, particularly after adjustment for fasting C-peptide and BMI.",
author = "Y. Yogev and R. Chen and M. Hod and D.R. Coustan and J.J.N. Oats and B.E. Metzger and L.P. Lowe and A.R. Dyer and Elizabeth Trimble and David McCance",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.ajog.2010.01.024",
language = "English",
volume = "202",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

Yogev, Y, Chen, R, Hod, M, Coustan, DR, Oats, JJN, Metzger, BE, Lowe, LP, Dyer, AR, Trimble, E & McCance, D 2010, 'Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia', American Journal of Obstetrics and Gynecology, vol. 202, no. 3. https://doi.org/10.1016/j.ajog.2010.01.024

Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study : preeclampsia. / Yogev, Y.; Chen, R.; Hod, M.; Coustan, D.R.; Oats, J.J.N.; Metzger, B.E.; Lowe, L.P.; Dyer, A.R.; Trimble, Elizabeth; McCance, David.

In: American Journal of Obstetrics and Gynecology, Vol. 202, No. 3, 01.03.2010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study

T2 - preeclampsia

AU - Yogev, Y.

AU - Chen, R.

AU - Hod, M.

AU - Coustan, D.R.

AU - Oats, J.J.N.

AU - Metzger, B.E.

AU - Lowe, L.P.

AU - Dyer, A.R.

AU - Trimble, Elizabeth

AU - McCance, David

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Objective: The purpose of this study was to examine associations of fasting C-peptide, body mass index (BMI), and maternal glucose with the risk of preeclampsia in a multicenter multinational study. Study Design: We conducted a secondary analysis of a blinded observational cohort study. Subjects underwent a 75-g oral glucose tolerance test at 24-32 weeks' gestation. Associations of preeclampsia with fasting C-peptide, BMI, and maternal glucose were assessed with the use of multiple logistic regression analyses and adjustment for potential confounders. Results: Of 21,364 women who were included in the analyses, 5.2% had preeclampsia. Adjusted odds ratios for preeclampsia for 1 SD higher fasting C-peptide (0.87 ug/L), BMI (5.1 kg/m), and fasting (6.9 mg/dL), 1-hour (30.9 mg/dL), and 2-hour plasma glucose (23.5 mg/dL) were 1.28 (95% confidence interval [CI], 1.20-1.36), 1.60 (95% CI, 1.60-1.71), 1.08 (95% CI, 1.00-1.16), 1.19 (95% CI, 1.11-1.28), and 1.21 (95% CI,1.13-1.30), respectively. Conclusion: Results indicate strong, independent associations of fasting C-peptide and BMI with preeclampsia. Maternal glucose levels (below diabetes mellitus) had weaker associations with preeclampsia, particularly after adjustment for fasting C-peptide and BMI.

AB - Objective: The purpose of this study was to examine associations of fasting C-peptide, body mass index (BMI), and maternal glucose with the risk of preeclampsia in a multicenter multinational study. Study Design: We conducted a secondary analysis of a blinded observational cohort study. Subjects underwent a 75-g oral glucose tolerance test at 24-32 weeks' gestation. Associations of preeclampsia with fasting C-peptide, BMI, and maternal glucose were assessed with the use of multiple logistic regression analyses and adjustment for potential confounders. Results: Of 21,364 women who were included in the analyses, 5.2% had preeclampsia. Adjusted odds ratios for preeclampsia for 1 SD higher fasting C-peptide (0.87 ug/L), BMI (5.1 kg/m), and fasting (6.9 mg/dL), 1-hour (30.9 mg/dL), and 2-hour plasma glucose (23.5 mg/dL) were 1.28 (95% confidence interval [CI], 1.20-1.36), 1.60 (95% CI, 1.60-1.71), 1.08 (95% CI, 1.00-1.16), 1.19 (95% CI, 1.11-1.28), and 1.21 (95% CI,1.13-1.30), respectively. Conclusion: Results indicate strong, independent associations of fasting C-peptide and BMI with preeclampsia. Maternal glucose levels (below diabetes mellitus) had weaker associations with preeclampsia, particularly after adjustment for fasting C-peptide and BMI.

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-77649166899&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2010.01.024

DO - 10.1016/j.ajog.2010.01.024

M3 - Article

AN - SCOPUS:77649166899

VL - 202

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -